TLDR: Lantern Pharma has launched a new AI-powered module within its proprietary RADR® platform, designed to predict the efficacy and optimize the development of combination cancer therapies. This innovation targets the rapidly growing $50 billion cancer market and has already successfully guided an FDA-cleared Phase 1B/2 clinical trial, promising to significantly reduce drug development timelines and costs.
DALLAS, Texas – Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company focused on transforming oncology drug discovery and development, today announced the launch of a groundbreaking AI-powered module within its proprietary RADR® platform. This innovative module is specifically engineered to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment.
The introduction of this AI module is poised to make a significant impact on the global combination cancer therapy market, which is projected to exceed $50 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.5%. Over 60% of cancer patients currently receive DDAs or DDRis as part of their clinical treatment, underscoring the broad applicability and potential of this new technology.
The module’s development is rooted in extensive data analysis, having been trained on a robust dataset derived from 221 DDA-DDRi combination-arm clinical trials. This comprehensive review involved 22 DDAs and 46 DDRis, with 89 trials providing interpretable outcomes that were scored for clinical effectiveness, safety, and biomarker-driven responses. This rigorous data-driven approach allows the AI to leverage machine learning to predict which drug combinations will be most effective for specific patient populations while simultaneously minimizing toxicity risks.
According to Lantern Pharma, this AI-powered approach is expected to reduce combination therapy development timelines and costs by approximately one-third compared to traditional methods, enabling faster and more cost-effective development of tailored therapeutic regimens. The efficacy of the new module has already been demonstrated through its successful guidance in the design of Lantern’s FDA-cleared Phase 1B/2 clinical trial. This trial combines LP-184 with olaparib for the treatment of triple-negative breast cancer (TNBC), showcasing the platform’s immediate practical application and validation.
Panna Sharma, CEO and President of Lantern Pharma, emphasized the significance of this advancement, stating, “This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments.” The module integrates genomic, transcriptomic, and clinical data to predict synergistic drug interactions, optimize therapeutic outcomes, and identify biomarker-defined patient subpopulations most likely to respond to specific combinations. Key insights from the company’s research also highlight the promise of non-PARP inhibitor combinations and the critical role of biomarkers, such as TP53 mutations, in predicting treatment response, alongside methods for reducing toxicity in combination regimens.
Also Read:
- CellBot Revolutionizes Medical Research with AI on CellVerse Platform
- Generative AI Revolutionizes De Novo Design of Therapeutic Nanobodies
This strategic launch further solidifies Lantern Pharma’s position at the forefront of AI-driven oncology, promising to accelerate the delivery of more precise and effective cancer therapies to patients worldwide.
